Pemigatinib (Pemazyre) is a targeted therapy for specific genetic abnormalities, mainly indicated for the treatment of cholangiocarcinoma with FGFR2 genetic abnormalities and myeloid/lymphoid neoplasms with FGFR1 genetic abnormalities.

Dosage and Administration of Pemigatinib (Pemazyre) - Recommended Doses

Routine Dosage Regimens

The standard recommended dose of pemigatinib is 13.5 mg, administered orally once daily.

Patients with cholangiocarcinoma shall adopt an intermittent dosing schedule: continuous administration for 14 days followed by a 7-day drug holiday, forming a 21-day treatment cycle.

Patients with myeloid/lymphoid neoplasms need to take the medication continuously once daily until disease progression or intolerable toxic reactions occur.

Administration Precautions

The tablets should be swallowed whole; do not chew, crush, or dissolve them.

It is recommended to take the medication at a fixed time every day, either with or without food.

If a dose is missed for more than 4 hours or vomiting occurs after administration, do not take a supplementary dose and resume the next scheduled dose as planned.

Dosage Adjustment of Pemigatinib (Pemazyre)

Dosage Adjustment for Adverse Reactions

In case of retinal pigment epithelial detachment (RPED):

For asymptomatic patients with stable examination results, continue treatment at the original dose.

For patients with symptoms or worsening findings on examination, suspend the medication and resume treatment at a reduced dose after symptom relief.

Management of Hyperphosphatemia

Initiate phosphate-lowering treatment when serum phosphate level exceeds 7 mg/dL; suspend the medication if the level does not drop below 7 mg/dL within 2 weeks.

Immediately initiate phosphate-lowering treatment when serum phosphate level exceeds 10 mg/dL; suspend the medication if the level does not drop below 10 mg/dL within 1 week.

Usage in Special Populations of Pemigatinib (Pemazyre)

Patients with Hepatic or Renal Impairment

For patients with severe renal impairment, the recommended dose is adjusted to 9 mg, and the corresponding dosing schedule shall be adopted according to the indication.

Patients with severe hepatic impairment also need to have the dose adjusted to 9 mg.

Pregnant Women

Based on animal study results, pemigatinib may cause fetal harm.

Pregnant women should be informed of the potential risks to the fetus.

Patients of Childbearing Potential

Females of childbearing potential should adopt effective contraceptive measures during treatment and within 1 week after the last dose.